Vizsgálati helyszín
Icon Cancer Centre Hobart
Hobart, 7000, AusztráliaMég nincs intézményhez kötve
Az itteni vizsgálatok
Miről szól a helyszín 16 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis9 vizsgálat
- 2. fázis6 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Toboroz8 vizsgálat
- Fő szponzor
- Pfizer4 vizsgálat
- Daiichi Sankyo2 vizsgálat
- Gilead Sciences2 vizsgálat
- Regeneron Pharmaceuticals2 vizsgálat
- Verastem, Inc.2 vizsgálat
- és még 4
Futó vizsgálatok
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795· 2. fázis· Verastem, Inc.· Forrás
Contact: Icon Cancer Centre Hobart
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· 2. fázis· Verastem, Inc.· Forrás
Contact: Louise Nott
Toboroz
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· 2. fázis· Genmab· Forrás
Toboroz
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· 3. fázis· Pfizer· Forrás
Toboroz
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· 2/3. fázis· Pfizer· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478· 2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672· 3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
NCT04291885· 2. fázis· Melanoma and Skin Cancer Trials Limited· Forrás
Fut, nem toboroz
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353· 3. fázis· University of Sydney· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek